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Abstract
Objective To quantify the separate contributions of menopausal hormone
treatment and mammography screening activities on trends in incidence
of invasive breast cancer between 1987 and 2008.
Design Population study using aggregated data analysed by an extended
age-period-cohort model.
Setting Norway.
Population Norwegian women aged 30-90 between 1987 and 2008,
including 50 102 newly diagnosed cases of invasive breast cancer.
Main outcomes measures Attributable proportions of mammography
screening and hormone treatment to recent incidence of invasive breast
cancer, and the remaining variation in incidence after adjustment for
mammography screening and hormone treatment.
Results The incidence of invasive breast cancer in Norway increased
steadily until 2002, levelled off, and then declined from 2006. All
non-linear changes in incidence were explained by use of hormone
treatment and mammography screening activities, with about similar
contributions of each factor. In 2002, when the incidence among women
aged 50-69 was highest, an estimated 23% of the cases in that age
group could be attributed to mammography screening and 27% to use
of hormone treatment.
Conclusions Changes in incidence trends of invasive breast cancer
since the early 1990s may be fully attributed to mammography screening
and hormone treatment, with about similar contributions of each factor.
Introduction
In most countries the incidence of invasive breast cancer has
increasedsteadilyforseveraldecades,butrecentlytheincidence
has levelled off or declined in many developed countries.
1-4 It
is well known that use of both hormone treatment and
mammography screening increases the risk of breast cancer,
5 6
and it has been suggested that the recently observed decrease
inincidencemayreflectthereductioninhormonetreatmentuse
duringrecentyears.
1 2 4 7-10Arelativedecreaseinincidencecould
also be expected after the first wave of public mammography
screening,sincetheinitialscreeningmaydetectalargernumber
ofpreclinicalcasescomparedwithsubsequentscreeningrounds.
5
In several countries, systematic mammography screening was
introduced around the time when the use of hormone treatment
was at its highest, and both factors involve roughly the same
age groups of women.
5 It is therefore a challenge to separate
the contributions of hormone treatment and mammography
screening on trends in incidence of breast cancer.
Norway has a high quality nationwide cancer registry,
11 county
specificinformationonsalesofhormonetreatment,andapublic
mammography screening programme that was gradually
introduced between 1995 and 2004. This makes Norway well
suited for the study of how hormone treatment and
mammographyscreeningcouldhavecontributedtotheobserved
patterns in breast cancer. Using Norwegian data we separated
the contributions of hormone treatment use and mammography
screeningonrecenttrendsinincidenceofinvasivebreastcancer.
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Weuseddatafromdifferentsourcestoseparatethecontributions
of mammography screening and hormone treatment use on
recentincidencetrendsininvasivebreastcancer,includingdata
on incident cases of breast cancer, population figures, sales
figures for hormone treatment, and data on public
mammography screening patterns (see web extra figure on
bmj.com).
The clinical treatment of ductal carcinoma in situ and invasive
breastcancerissimilar,buttheirrecenttrendsinincidencediffer
and the detection of ductal carcinoma in situ seems to be
considerably more strongly associated with mammography
screeningthanwithinvasivedisease.
12 13Thereforewerestricted
the end point of this study to invasive breast cancer, to achieve
a clear and more uniform analysis where the results are easier
tointerpret.Overall,theproportionofcasesofductalcarcinoma
in situ has never exceeded 10% of breast malignancies in
Norway. However, in the overall evaluation of the effects of
mammography screening, ductal carcinoma in situ should be
included in the analysis, as a large proportion of cases may
represent over-diagnoses.
14 15
For each of the 19 Norwegian counties we aggregated annual
populationdataanddataoninvasivebreastcancer.Wecollected
databyoneyearagegroupsforeachcalendaryear,andincluded
allwomenbetween30and90yearsofageandlivinginNorway
during the study period, from 1987 to 2008. This age range was
chosen to strengthen contrasts between cohorts with different
levels of hormone treatment and mammography screening, and
simultaneouslytoavoidagegroupswithalownumberofbreast
cancer cases that would yield imprecise estimates. Reporting
of cancer to Norway’s cancer registry is mandatory, and
informationisobtainedseparatelyfromclinicians,pathologists,
anddeathcertificates.Only0.2%ofcancercasesareascertained
fromdeathcertificatesonly.
11Norwegiancitizensareidentified
byaunique11digitpersonalidentificationnumberthatincludes
dateofbirth.Theauthoritieskeeparecordofplaceofresidence,
and vital status is carefully monitored. Thus the population at
risk of breast cancer is clearly defined.
16
In1995theNorwegianbreastcancerscreeningprogrammewas
initiated by the Norwegian government. It was first established
in four counties in 1995/6, then gradually extended to the
remaining 15 counties, until the programme reached national
coverage in 2004/5.
13 17 Biannually, all women aged between
50 and 69 years receive a written invitation to the screening
programme, and two view mammograms are independently
evaluated by two readers. Attendance to the programme has
been about 78%.
18 For administrative purposes, almost all
women are invited by birth cohort. This results in a small
departure from the official screening age, but for all practical
purposes we assumed that screening took place between ages
50 and 69, when the screening variables were calculated.
Beforeandalsoaftertheintroductionofpublicscreening,private
clinicshaveofferedmammographyscreening.Theexactvolume
of the private activity is not known, but a questionnaire survey
atthefirstpublicscreeningrevealedthatasubstantialproportion
ofwomenhadattendedmammographyscreeningbeforeentering
the public screening programme.
18 Preliminary inquiries at the
Norwegian cancer registry, however, indicate that screening at
privateclinicsonlycontributestoasmallproportionofthetotal
number of screening examinations after the public screening
programme was introduced.
All sales of hormone treatment in Norway are recorded in the
wholesales drug statistics database at the Norwegian Institute
of Public Health. Total sales statistics have been available in
electronic form since 1987, with separate statistics for
preparations containing only oestrogens (G03C according to
the Anatomical Therapeutic Chemical classification, www.
whocc.no/) and combined preparations of progestogens and
oestrogens (G03F). Since 1999, county specific data on sales
of hormone treatment have been available in electronic form
from all 19 counties. Between 1992 and 1998, county specific
datawereavailableinelectronicformonlyinfourcounties.For
the other counties, and before 1992, county specific data on
sales of hormone treatment had to be collected from paper lists
and adjusted according to newer Anatomical Therapeutic
Classification and defined daily dose definitions. Therefore we
collected county specific data for 1987, 1991, and 1995 to use
intheestimationofthedistributionofsalesindifferentcounties
before 1999 (see web extra table on bmj.com for an overview
of data).
The statistics on sales do not include the age distribution of
users, but in 2004 the Norwegian prescription database was
established to include all prescribed drugs in Norway. Thus
prescriptiondrugsarenowregisteredonapersonalidentification
form, and we used the age of the registered users to relate
hormonetreatmenttothewomen’sage.Informationonagewas
collected separately for total use, use of oestrogens alone, and
use of oestrogen-progestogen combinations.
Statistical methods and modelling approach
Choice of a basic breast cancer incidence model
Age-period-cohortmodelsmayseparatetheeffectsofagefrom
the effects of risk factors related to calendar period and birth
cohort.
19 20Theincidenceofbreastcancerincreaseswithage,
5 21
and there is a substantial birth cohort effect owing to variation
in age at menarche and variation in parity patterns.
5 22 We
thereforeincludedseparatevariablesforage,cohort,andperiod
effects,andgraduallyextendedthemodeltoincludeinformation
on mammography screening and use of hormone treatment.
5 23
Thus we could evaluate the association of hormone treatment
andmammographyscreeningwithtrendsinincidenceandassess
the remaining period effects that could not be accounted for by
age, cohort, hormone treatment, and mammography screening.
Screening variables
We modelled the potential effect of screening as suggested
previously,
5 using three variables that cover different phases of
themammographyscreeningprogramme.Onevariablecovered
thefirstscreeninground,withtheexpectedincreaseinincidence
of breast cancer owing to the detection of prevalent but not yet
detected cases. A second variable covered the subsequent
screening rounds. A third variable modelled a potential drop in
incidence for women who had already been screened, since
some breast cancers were probably detected already as part of
earlier mammography screening. Motivated by previously
estimated mammography screening lead time,
24 25 we designed
a third variable to cover the first five years after leaving the
screening programme. All screening variables were modelled
as continuous proportions calculated for each age, period, and
county combination.
Hormone treatment variables
For each combination of age, period, and county we estimated
the proportion of current users of hormone treatment. For years
with limited information on county specific sales of hormone
treatment (see web extra table), we distributed the use of
hormone treatment between counties using linear interpolation
betweenthepreviouslyobservedcountyspecifichormonesales
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RESEARCHand the next county specific hormone sales. Although
information on age at hormone treatment was provided by the
Norwegian prescription database, this only dates back to 2004,
so we used the age distribution in 2004 as an approximation for
the age distribution of use before 2004. The data showed that a
small proportion of hormone treatment was prescribed to men.
In calculating the hormone treatment variable, we accounted
for the use among men and scaled the hormone treatment
variable according to reported daily doses. As a time lag
probably exists between use of hormone treatment and the
potential influence on trends in incidence of breast cancer, we
examined the effects of adding different lag times to the
hormonetreatmentdatawhencalculatingthehormonetreatment
variable.
For the period covered by our study, we estimated that among
women aged 30-90 years hormone treatment was used by 3%
in 1987, 15% in 2000, and by 6% in 2008. In the 50-69 year
age group, the corresponding proportions were 7%, 33%, and
12%.
Statistical methods and modelling age, period,
and cohort effects
Based on county specific one year age-period tables, we
modelledtheincidenceofbreastcancerusinglog-linearPoisson
regression.
19 20 The full model could be written as:
Ra,p=exp(Aa+Cc+Pp+S1×scr1×scr2+S3×scr3+H×ht)
whereRa,pistheincidencerateinagegroupaincalendarperiod
p, Aa is the age component for age group a, Cc is the cohort
component for birth cohort c, Pp is the period component for
year p, and S1, S2, and S3 are regression coefficients
(parameters) for the screening variables scr1, scr2, and scr3,
the initial screening variable scr1, the subsequent screening
variable,scr2,andthefirstfiveyearsafterleavingthescreening
programme variable, scr3, respectively, and H is the regression
coefficient for the hormone treatment variable ht.
In practice, the cohort variable will model effects related to
changes in fertility patterns (for example, age at first birth,
numberofchildren)andotherknownriskfactorsrelatedtobirth
cohort. Age is another key variable, owing to the strong age
related increase in incidence.
5 As for period effects, we tested
their statistical contribution and removed effects that were not
statisticallysignificantfromthemodel.Formodelcomparisons,
we evaluated the differences in model deviance and the related
P values from goodness of fit tests at a 5% significance level
using the difference in the observed deviance and the degrees
of freedom between a set of nested models. To evaluate overall
model fit, we studied over-dispersion using methods of quasi
likelihood,andtestedforanystatisticallysignificantdeviations
from the random variation of the assumed model.
To assess statistical uncertainty, we calculated 95% confidence
intervals for the estimated regression coefficients. In plots, we
estimated smoothed curves using the R statistical package
“supsmu” implementation of Jerome Friedman super smoother
algorithm (where the degree of smoothing is chosen by
leave-one-out cross validation).
26 Since the evaluation of time
related changes of incidence curves is not suited to orderly
confidence intervals, we used bootstrap replications to guide
theevaluationofestimatedcurvesofageandcohortcomponents
(not shown). All calculations, simulations, and plots were done
using the R statistical package.
26
Results
Incidence trends of invasive breast cancer in
Norway, hormone treatment use, and
screening
The age adjusted incidence of invasive breast cancer has
increased steadily in Norway from the 1950s until 2002,
27 after
which the incidence levelled off, followed by a modest decline
(fig 1⇓). By studying age specific incidence and grouping
womeninagegroups(30-49,50-69,and70-90years),thelarge
variation that explains the pronounced changes since the 1990s
is among women aged 50-69 years. In this age group the
incidence steeply increased during the late 1990s, before a
gradualbutmodestdeclinefromaround2003.Duringthisperiod
changeswereonlymoderateinyounger(30-49years)andolder
(70-90 years) women, with a slight increase in the younger age
group and a moderate decline in the older age group.
SalesofhormonetreatmentincreasedsharplyinNorwayduring
the 1990s and declined shortly after 2000, following similar
patternsinallNorwegiancounties(datanotshown).Theselarge
changes occurred around the time that public mammography
screeningwasintroduced(fig1),andcorrespondwiththesharp
increase in breast cancer incidence in the late 1990s. Public
mammography screening was offered to women aged 50-69,
andprescriptiondataonhormonetreatmentshowthattreatment
was mainly used among women in the age group 50-69 years,
with the peak consumption between ages 55 and 60 (data not
shown). For the 19 Norwegian counties combined, a strong
increaseinhormonetreatmentoverlappedwiththeintroduction
of mammography screening, both for age groups and birth
cohorts.Althoughthetimetrendsweresimilarbetweencounties,
the amount of hormone treatment varied (data not shown). The
mammography screening programme was also gradually
introduced by county, and therefore hormone treatment sales
peaked at different phases of the programme.
Model fitting
A classic age-period-cohort model showed considerably better
modelfit,withalargeandsignificantdeclineinmodeldeviance
(−20 078 with 178 fewer degrees of freedom, P<0.001, table
1⇓) compared with using a combined breast cancer rate for all
age groups, cohorts, and periods. Significant non-linear cohort
effects were still observed (P<0.001). By including screening
variables the model fit was further improved (model deviance
−467 with three fewer degrees of freedom, P<0.001), but
considerableandsignificantnon-linearperiodeffectsremained
that could not be explained by age, cohort, or mammography
screening variables (P<0.001, fig 2⇓). By further extending the
model to include sales of hormone treatment, the model fit
improved further (model deviance −68 with one less degrees
of freedom, P<0.001), whereas the non-linear period effects
were strongly reduced, leaving only small and non-significant
non-linear period effects (model deviance 30 with 20 more
degrees of freedom, P=0.07, fig 2). Since all significant
non-linear period effects were explained by mammography
screening and use of hormone treatment, an age-cohort model
with screening and hormone treatment variables was chosen as
the final model, without any period variables. After taking
hormone treatment and screening into account, no statistically
significant non-explained variation in incidence remained (the
P value for potential statistical over-dispersion was 0.08 for the
final model).
To account for a possible induction period related to the
association of hormone treatment with changes in incidence of
breast cancer, changes in model deviance were examined after
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treatment variable (fig 3⇓). A time lag of one year gave the best
fitandwasusedinthefinalanalysis,butalltimelagsfromzero
to three years yielded similar model fit. The analysis was also
extended to estimate the separate contributions of using
oestrogenaloneandcombinationsofoestrogenandprogestogen,
andapplieddifferentcombinationsoftimelagsforeachvariable.
For oestrogen alone, the best model fit was observed using a
oneyeartimelag,whereasforthecombinedhormonetreatment
formulations, a time lag of two years provided the best fit.
However, the overall model fit was not improved by extending
themodeltodistinguishbetweenthetwomaintypesofhormone
treatment, and the associations of the two treatment variants
with risk of breast cancer did not differ substantially (table 2⇓).
Estimated effects of screening and hormone
treatment
Overall, there was an estimated increase in invasive breast
cancerincidenceof59%(95%confidenceinterval52%to67%)
associated with being invited to the initial screening (table 2),
and for the subsequent screening there was an increase of 16%
(11% to 21%) associated with being in the target age group.
During the first five years after leaving the screening
programme’s target age group, incidence decreased by an
estimated 14% (7% to 21%). The relative risk of breast cancer
associated with use of hormone treatment was estimated to be
2.2 (1.9 to 2.5; table 3⇓). Colinearity between the estimates for
hormone treatment and mammography screening was not
considerable,thusthenegativecorrelationbetweenthehormone
treatmentestimateandthethreescreeningrelatedestimateswas
onlymoderate(−0.14forinitialscreening,−0.07forsubsequent
screening, and −0.06 for leaving the screening programme’s
target group).
Theestimatedrelativerisksrelatedtouseofhormonetreatment
based on oestrogen alone compared with combinations of
oestrogenandprogestogendidnotdiffersubstantially(table2):
relative risk 2.2 (95% confidence interval 0.8 to 5.7) and 2.2
(1.4 to 3.4).
Age and cohort effects
The reduction in incidence of invasive breast cancer for birth
cohorts born between 1900 and 1930 was modest (fig 4⇓). In
subsequent birth cohorts, a sharp increase was observed until
the cohorts born around 1960. After 1960, the number of cases
was still low but the incidence may have stabilised (fig 4).
After taking birth cohort, mammography screening, and
hormone treatment into account, the age specific incidence of
breastcancersteadilyincreasedexceptforafairlystableplateau
at around age 50 (figs 3 and 4). One hundred bootstrap
replications were visually examined to assess the significance
of the slower increase in incidence around age 50, and in all
replications the incidence levelled off at around age 50 (data
not shown). This confirms the well known plateau in incidence
around the age of menopause,
21 which has not been apparent in
recent decades in Norway.
3
Estimated influence of hormone treatment
use and screening on overall trends in
incidence
After taking hormone treatment and mammography screening
into account, the strong increase in incidence of invasive breast
cancer in the 1990s disappeared, as did the subsequent decline
from around 2006 (fig 4). The contribution of each factor in
explainingtherecentvariationintrendsinincidenceofinvasive
breast cancer was similar, with a slightly stronger estimated
effect of mammography screening than of hormone treatment
(table 4⇓ and fig 4). For most periods, however, the proportion
of invasive breast cancer that may be attributed to hormone
treatment seemed to be slightly larger than the attributable
proportion of mammography screening (table 4⇓ and fig 4). In
2002, when breast cancer incidence was at its highest among
women aged 50-69, 23% of cases in that age group may be
attributed to mammography screening and 27% to hormone
treatment (table 3). The results indicate that among women in
their 50s, as many as one in three cases of breast cancer that
occurred around 2000 may be attributed to hormone treatment
(table 4).
Discussion
Prominent and statistically significant associations were found
for both hormone treatment and mammography screening that
could fully explain recent trends in breast cancer incidence in
Norway. In the analysis, we extended the classic
age-period-cohort model to include information on the use of
hormone treatment and patterns of organised national
mammography screening. The information on hormone
treatment and mammography screening improved the model
substantially, with no remaining statistically significant
over-dispersion or non-linear period effects and no substantial
departures from the historical gradual increase in incidence of
invasive breast cancer. The results suggest that the variation in
incidence during the past 20 years may be caused by the use of
hormone treatment and mammography screening activities.
A common challenge in age-period-cohort models is that the
linear components of period and cohort effects cannot be
separated, and the choice of contrast is therefore decisive for
the results.
19 20 23 This problem does not apply to our results,
because the period components did not contribute significantly
to the model and were excluded from the final analysis.
Without access to individual data we could not study effects of
different durations of hormone treatment, or estimate separate
effects of when treatment started or finished. Without
randomisationofstudyparticipantsitisalsodifficulttoexclude
the possibility that confounding by other factors could play a
part.Giventhehighqualitydataonbreastcancer
11andthegood
modelfit,however,theobservedestimatesareprobablyreliable.
We used imputation for some data points related to hormone
treatment, but the time related changes in hormone treatment
were gradual and the total use for each calendar year is known.
Thereforetheimpactoftheseimputationswasprobablylimited.
We also had to make imputations based on assumptions of the
agedistributionofhormonetreatmentuse,sincethisinformation
was not available before 2004 and not available for the quarter
of hormone treatment that does not require a prescription. The
assumption that the age distribution of hormone treatment up
to 2004 was similar to the age distribution after 2004, and that
the age distribution of users of over the counter drugs and
prescribed drugs was similar, probably adds some uncertainty
to the estimates. The good model fit is, however, an indication
that the effect of this potential attenuation may be limited.
The age-incidence curve after taking hormone treatment use
and mammography screening into account, corresponded well
withhistoricalcurvesonagerelatedincidenceofinvasivebreast
cancer,
21 and includes the classic plateau around menopause.
21
Any departures from the targeted screening age have probably
hadlittleimpactonthegivenestimates,indicatedbythesmooth
estimates for age specific incidence around the assumed
screening age (fig 4).
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RESEARCHA substantial proportion of women in Norway attended
screening at private clinics before the official programme was
established,
18 and some women may have continued to do so.
This could have attenuated the estimated contributions of both
the initial public screening and the women who left the
programme after age 69. It is also possible that some doctors
recommended additional mammography among women who
usedhormonetreatment,whichmayhaveinflatedtheestimated
association of hormone treatment. For private screening to bias
the results substantially, however, we would have expected to
see non-linear period effects or significant over-dispersion
introduced by variations in private screening by period. The
lack of such observations suggests that non-registered private
screening has not undermined the validity of our results.
We also carried out a separate analysis to distinguish between
the use of oestrogens alone and combined preparations of
oestrogen and progestogen, but found no evidence for any
difference in the estimated effects. However, plots of the
simultaneous confidence region for the two estimates indicated
internal colinearity (figure not shown). Both preparations had
similar curves for period and age, which make it difficult to
estimate any separate effects using aggregated data.
Comparison with other studies
Itseemsclearthatboththeinitialandthesubsequentscreenings
substantially increased the incidence of invasive breast cancer,
and that a reduction in incidence occurred after leaving the
screening programme. These observations correspond with the
findings of others.
5 28 Our estimated effects were moderate
comparedwithreportedestimatesofSwedishdata.
5TheSwedish
studyfoundthatbeinginvitedtoinitialscreeningwasassociated
withmorethanadoublingoftheincidenceandthatbeinginvited
to subsequent screening was associated with an increase in
incidence of 34%. The researchers also reported that leaving
the programme’s target group was associated with a reduction
in incidence of 32%. In comparison with that study,
5 we had
access to more detailed information, including county specific
data on sales of hormone treatment, which may provide more
precise estimates.
In the Women’s Health Initiative randomised trial, the relative
risk of breast cancer associated with current use of hormone
treatment was 1.26
6; our corresponding estimate was 2.17. In
the Norwegian prescription database the number of hormone
treatmentusersishighcomparedwiththenumberofprescribed
daily doses (data not shown), suggesting that many women use
hormone treatment for a short period only. If breast cancer risk
is only moderately increased by short term use, our estimates
would be attenuated by the large number of short term users.
Therefore duration of hormone treatment use is not likely to
explain the stronger association of hormone treatment in our
study compared with that of the Women’s Health Initiative
randomised trial. In addition, we found that use of hormone
treatment was high in the mammography screening age group,
and the interaction between hormone treatment and
mammography screening could have further biased the
association of hormone treatment towards the null since the
treatment is known to decrease the sensitivity of the screening
test.
29 Therefore, the association with breast cancer risk is a
possible indication for a genuinely stronger effect of hormone
treatment use in Norway than expected from the Women’s
Health Initiative trial.
Other studies suggest that the combined hormone treatment
preparations typically used in Europe may be more strongly
associated with breast cancer risk than preparations typically
used in the United States.
29-32 In the Million Women Study in
theUnitedKingdom,therelativeriskofbreastcancerassociated
with all current use of hormone treatment was 1.66,
30 and the
relativeriskassociatedwithuseofcombinedhormonetreatment
preparations was 2.0. Similarly, in a Norwegian cohort study
with individual data, the relative risk of current hormone
treatment use was estimated to be 2.1.
33 Hormone treatment
preparations in Norway differ from those in the United States,
and combined preparations with a testosterone derived
progestogen are preferred. These provide a higher dose of
progestogens than do other preparations.
31 Differences in risk
estimates attributed to use of hormone treatment may therefore
be caused by differences in dose or drug properties between
preparations. Our results confirm the short lag time that others
have reported from use of hormone treatment until a change in
breastcancerincidenceisobserved,
30 33suggestingthathormone
treatment may promote the growth of an already initiated
tumour. Whether tumours that may be attributed to hormone
treatment are less aggressive than other tumours is still not
resolved.
34 35
We observed a steep increase in incidence of invasive breast
cancer among cohorts born from the 1930s until the late 1950s,
whereasincohortsbornbefore1930andafter1960thechanges
were moderate. Judged from the literature, it is difficult to
identify cohort specific factors that may explain these
differences, suggesting that a combination of several changing
factors may be important.
22 36
Implications of the current study
Recently the frequency of pre-invasive ductal carcinomas in
situ have increased sharply. Ductal carcinoma in situ was not
included in the present study because trends in incidence for
this condition differ substantially from those of invasive breast
cancer. Effects of mammography screening are also likely to
differ, and hormone treatment use and other risk factors may
haveadifferentinfluenceonductalcarcinomainsitucompared
withinvasivedisease.Basedonthefindingsofpreviousstudies,
including ductal carcinoma in situ in our study would probably
have increased the fraction of breast malignancies that may be
attributed to mammography screening.
13 However, it is likely
that the effect would be limited, as the proportion of ductal
carcinoma in situ of Norwegian breast malignancies never
exceeded 10% during the observation period.
Over-diagnosisassociatedwithmammographyscreening,
28 37 38
and subsequent overtreatment, may represent one of the most
pressing challenges of breast cancer screening. We found a
strong positive association of mammography screening with
recent incidence of invasive breast cancer; however, our study
was not designed to assess the proportion of cancers detected
bymammographythatmayrepresentover-diagnosis.Thatwould
require a more detailed analysis of the potential reduction in
incidence after screening and also an analysis of trends in
incidenceofductalcarcinomainsitu,asasubstantialproportion
of these cases most likely represent over-diagnosis of breast
cancer.
39Nonetheless,anevaluationofover-diagnosisrequires
reliable estimates of the expected incidence of breast cancer in
the absence of screening. Therefore our study may be an
appropriate basis for future studies of over-diagnosis.
Insummary,ourresultssuggestthattherecentchangesintrends
in incidence of invasive breast cancer may be explained by a
combinationofmammographyscreeningpatternsandhormone
treatment use, with similar contributions of each factor.
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RESEARCHWhat is already known on this topic
After decades of a consistent increase, the incidence of invasive breast cancer has recently declined in many developed countries
Reduced use of hormone therapy and completion of the first wave of mammography screening have been suggested as explanatory
factors
The importance of each factor’s contribution is, however, uncertain
What this study adds
The changes in incidence of invasive breast cancer observed in many developed countries may be attributed to mammography screening
and hormone treatment use, with about similar contributions of each factor
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RESEARCHTables
Table 1| Model fit for alternative models: basic age-period-cohort model, then model extended with screening variables and with screening
variables and hormone treatment using either shared or separate modelling of hormone treatment types
P values
Degrees of freedom Deviance Model Non-linear period effects Over-dispersion Last variables added
<0.001 <0.001 <0.001 25 319 27 994 Age-period-cohort
<0.001 0.035 <0.001 25 316 27 527 Age-period-cohort+screening variables
0.074 0.082 <0.001 25 315 27 459 Age-period-cohort+screening variables+hormone
treatment
0.140 0.082 0.647 25 314 27 459 Age-period-cohort+screening variables+hormone
treatment including types*
*Grouped as oestrogens alone or oestrogen-progestogen combinations.
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RESEARCHTable 2| Estimated effects of hormone treatment and of being in target age group for breast cancer screening programme
Age-cohort model with screening variables
Variables Use of hormone treatment subgroups Use of hormone treatment*
1.57 (1.50 to 1.65) 1.59 (1.52 to 1.67) Scr1†: effect of starting screening programme
1.14 (1.09 to 1.20) 1.16 (1.11 to 1.22) Scr2‡: effect of being in screening programme
0.85 (0.78 to 0.92) 0.86 (0.79 to 0.93) Scr3§: effect of leaving screening programme
— 2.17 (1.85 to 2.54) Effect of hormone treatment with 1 year lag*¶
2.18 (0.83 to 5.71) — Effect of oestrogens alone with 1 year lag¶
2.22 (1.44 to 3.44) — Effect of oestrogen-progestogen combinations with 2 year
lag¶
Hormone treatment variable is scaled to estimate risk for ongoing use of hormone treatment.
*Shared estimate for oestrogens alone and oestrogen-progestogen combinations.
†Initial screening variable, defined as first two years covered by screening programme, since Norwegian programme uses biannual screening.
‡Subsequent screening variable, defined as two years plus period covered by screening programme.
§Variable covering first five years after leaving screening programme.
¶Applied lag of hormone treatment use variables where chosen by minimising model deviance in univariate age-cohort model with screening variables.
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RESEARCHTable 3| Estimated fractions of breast cancer cases attributable to hormone treatment and screening mammography
2008 2002 (peak incidence) 1987 Age group
50-69:
0.13 0.27 0.07 Hormone treatment attributable proportion
0.17 0.23 0.00 Screening attributable proportion
All studied age groups*:
0.09 0.19 0.04 Hormone treatment attributable proportion
0.08 0.12 0.00 Screening attributable proportion
*Age 30-90 years.
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RESEARCHTable 4| Estimated proportion of cases attributable to hormone treatment for selected age groups, based on age-cohort model with screening
variables and one year lag time after hormone treatment
2008 2006 2004 2002 2000 1998 1996 1994 1992 1990 1988 Age group
0.05 0.06 0.08 0.12 0.13 0.13 0.12 0.10 0.07 0.04 0.03 47 years
0.13 0.16 0.21 0.29 0.31 0.31 0.28 0.25 0.17 0.12 0.09 52 years
0.16 0.18 0.24 0.32 0.34 0.34 0.31 0.27 0.19 0.13 0.11 57 years
0.14 0.16 0.20 0.28 0.30 0.30 0.27 0.24 0.16 0.11 0.09 62 years
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RESEARCHFigures
Fig 1 (Top) Incidence of invasive breast cancer among Norwegian women, 1987-2008. Curves smoothed with Friedman’s
super smoother as implemented in statistical program R.
26 Points and curves are all age standardised relative to year 2000.
(Middle) Overview of Norwegian screening programme’s gradual introduction (calculated as approximated proportion of
woman in target group invited). (Bottom) Sales of hormone treatment in Norway, 1987-2008
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RESEARCHFig 2 Changes in invasive breast cancer incidence over study period and estimated age curves with and without correction
for either screening or combined screening and hormone treatment use. Calculated using age-cohort model with one year
lag added to hormone treatment variable
Fig 3 Model fit, measured by model deviance, for final age-cohort model, with screening variables and different time lags
added to hormone treatment variable. Lower model deviance implies better model fit, implying better accordance between
observed data and assumed model. Without information on hormone treatment, age-cohort model has a deviance of 27
505
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RESEARCHFig 4 Estimated cohort and age curves for incidence of invasive breast cancer from age-cohort model, with correction for
screening and hormone treatment use (one year lag)
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